With a competition delivering 96-100% success rate, MRK must be very careful selecting and recruiting their pts. Even few pts dropping out off the trial for whatever reasons will be perceived as a competitive failure of MRK HCV drug.
Consequently, I expect MRK to move slow with their HCV Ph III trial.
Market Data 
Markets 
AI
